---
title: "Reduced memory B-cell and antibody responses to mRNA COVID-19 boosters in IBD patients on anti-TNF"
id: "medrxiv-16-impaired-memory-b-cell-formation-after-mrna-based-covid-19-booster-vaccination"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-16-impaired-memory-b-cell-formation-after-mrna-based-covid-19-booster-vaccination"
content_type: "clinical_feed_article"
specialty: "Gastroenterology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.28.26359302v1?rss=1"
published_at: "2026-09-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Reduced memory B-cell and antibody responses to mRNA COVID-19 boosters in IBD patients on anti-TNF
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-16-impaired-memory-b-cell-formation-after-mrna-based-covid-19-booster-vaccination
- **Specialty:** [Gastroenterology](https://medichelpline.com/clinical-feed/gastroenterology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.28.26359302v1?rss=1)
- **Published At:** 2026-09-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Study compared antibody and **memory B cell (Bmem)** responses after mRNA COVID-19 booster vaccination in 27 inflammatory bowel disease (IBD) patients receiving intravenous **anti-TNF** therapy and 44 control participants. Blood was sampled at baseline, 1 month and 6 months post-booster. - Boosters administered were WH1/BA.5 **bivalent** or XBB.1.5 **monovalent** mRNA vaccines. Measurements included neutralizing antibody titers (infectious virus assay), RBD-specific serum IgG by ELISA, and flow cytometric immunophenotyping of RBD-specific Bmem to ancestral and Omicron subvariants (BA.1, BA.5, XBB.1.5, JN.1). - Serum RBD-specific **IgG** and neutralizing antibodies rose from baseline to 1 month after vaccination in anti-TNF patients, but absolute levels were lower than in controls. - Frequencies of RBD-specific **Bmem** recognizing ancestral, BA.5 and XBB.1.5 increased after vaccination in both groups but were significantly lower in anti-TNF-treated patients compared with controls. - The proportion of recently activated CD21lo RBD-specific Bmem increased after vaccination in both groups and was higher in anti-TNF patients than in controls, indicating altered activation phenotype. - Isotype distribution within antigen-specific Bmem differed: fewer antigen-specific Bmem in anti-TNF patients expressed **IgG4**, while more expressed **IgG3** or **IgD** after vaccination. - Vaccination increased the proportion of RBD-specific Bmem that cross-recognized multiple variants overall, but anti-TNF-treated patients had fewer Bmem capable of binding Omicron subvariants compared with controls, indicating reduced cross-reactivity. - Authors conclude that anti-TNF therapy in IBD is associated with reduced magnitude, durability and cross-reactivity of antibody and memory B-cell responses to COVID-19 boosters, suggesting impaired immune memory and supporting annual booster recommendations to prevent severe disease and transmission. - The work is a preprint (not peer reviewed). Ethics approvals were reported from Alfred Health, Monash University and Erasmus MC. Funded by the Australian Medical Research Future Fund (2016108).
## Clinical Analysis & Structured Key Points
Impaired memory B-cell formation after mRNA-based COVID-19 booster vaccination in patients with inflammatory bowel disease receiving anti-TNF treatment | medRxiv Skip to main content Impaired memory B-cell formation after mRNA-based COVID-19 booster vaccination in patients with inflammatory bowel disease receiving anti-TNF treatment View ORCID Profile Paul A. Gill , Lachlan R. Bradbury , Alina Wang , Julie Hogg , Kathryn Demase , Jo McKenzie , View ORCID Profile Holly A. Fryer , Daryl Geers , View ORCID Profile Luca M. Zaeck , Irene Boo , View ORCID Profile Mark P. Hogarth , View ORCID Profile Heidi E. Drummer , View ORCID Profile Rory D. de Vries , View ORCID Profile Robyn E. O'Hehir , Miles P. Sparrow , View ORCID Profile Menno C. van Zelm doi: https://doi.org/10.64898/2026.08.28.26359302 Paul A. Gill 1 Monash University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Paul A. Gill For correspondence: paul.gill{at}monash.edu Lachlan R. Bradbury 1 Monash University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Alina Wang 1 Monash University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Julie Hogg 2 Alfred Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kathryn Demase 2 Alfred Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jo McKenzie 2 Alfred Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Holly A. Fryer 1 Monash University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Holly A. Fryer Daryl Geers 3 Erasmus MC; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Luca M. Zaeck 3 Erasmus MC; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Luca M. Zaeck Irene Boo 4 Burnet Institute Find this author on Google Scholar Find this author on PubMed Search for this author on this site Mark P. Hogarth 4 Burnet Institute Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Mark P. Hogarth Heidi E. Drummer 4 Burnet Institute Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Heidi E. Drummer Rory D. de Vries 3 Erasmus MC; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Rory D. de Vries Robyn E. O'Hehir 1 Monash University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Robyn E. O'Hehir Miles P. Sparrow 2 Alfred Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Menno C. van Zelm 1 Monash University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Menno C. van Zelm Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background: Patients receiving anti-TNF treatment for chronic inflammatory disease display impaired antibody responses, but it remains unclear how immune memory formation is affected. We evaluated antibody responses and memory B cells (Bmem) after COVID-19 booster vaccination in inflammatory bowel disease (IBD) patients receiving anti-TNF treatment. Methodology: Blood was sampled at baseline, 1, and 6 months after WH1/BA.5 bivalent or XBB.1.5 monovalent vaccination from 27 IBD patients receiving intravenous anti-TNF and 44 controls. Neutralizing antibodies were measured using an infectious virus assay. SARS-CoV-2 spike receptor binding domain (RBD)-specific serum IgG was quantified by ELISA, and RBD-specific Bmem were immunophenotyped by flow cytometry using recombinant proteins from ancestral, Omicron BA.1, BA.5, XBB.1.5, and JN.1 variants. Results: Serum IgG to vaccine RBD and neutralizing antibodies in patients increased pre to 1 month post-vaccination, but were lower than controls. Ancestral-, BA.5- and XBB.1.5-specific Bmem increased after vaccination but were significantly lower in patients than controls. Within RBD-specific Bmem, frequencies of recently activated CD21lo cells were increased after vaccination, and were higher in patients than controls. Fewer antigen-specific Bmem in patients expressed IgG4, and more expressed IgG3 or IgD following vaccination. Following vaccination, more RBD-specific Bmem recognized multiple viral variants. However, patients had fewer Bmem that could bind to subvariants than controls. Conclusion: Antibody and Bmem responses to COVID-19 booster vaccination in anti-TNF-treated IBD patients displayed reduced capacity, durability and cross-reactivity, suggesting impaired immune memory for protection against breakthrough infection. This supports the recommendation for annual booster vaccination to prevent severe disease and viral spread. Competing Interest Statement MCvZ, REOH and PMH are inventors on a patent application related to this work. All other authors declare they have no conflict of interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee of Alfred Health gave ethical approval for this work (32/21) Ethics committee of Monash University gave ethical approval for this work (72794) Ethics committee of Erasmus University Medical Center (MEC-2022-0462) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present work are contained in the manuscript. Funder Information Declared Australian Medical Research Future Fund , 2016108 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . Back to top Previous Next Posted September 02, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Impaired memory B-cell formation after mRNA-based COVID-19 booster vaccination in patients with inflammatory bowel disease receiving anti-TNF treatment Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Impaired memory B-cell formation after mRNA-based COVID-19 booster vaccination in patients with inflammatory bowel disease receiving anti-TNF treatment Paul A. Gill , Lachlan R. Bradbury , Alina Wang , Julie Hogg , Kathryn Demase , Jo McKenzie , Holly A. Fryer , Daryl Geers , Luca M. Zaeck , Irene Boo , Mark P. Hogarth , Heidi E. Drummer , Rory D. de Vries , Robyn E. O'Hehir , Miles P. Sparrow , Menno C. van Zelm medRxiv 2026.08.28.26359302; doi: https://doi.org/10.64898/2026.08.28.26359302 Share This Article: Copy Citation Tools Impaired memory B-cell formation after mRNA-based COVID-19 booster vaccination in patients with inflammatory bowel disease receiving anti-TNF treatment Paul A. Gill , Lachlan R. Bradbury , Alina Wang , Julie Hogg , Kathryn Demase , Jo McKenzie , Holly A. Fryer , Daryl Geers , Luca M. Zaeck , Irene Boo , Mark P. Hogarth , Heidi E. Drummer , Rory D. de Vries , Robyn E. O'Hehir , Miles P. Sparrow , Menno C. van Zelm medRxiv 2026.08.28.26359302; doi: https://doi.org/10.64898/2026.08.28.26359302 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Allergy and Immunology Subject Areas All Articles Addiction Medicine (614) Allergy and Immunology (896) Anesthesia (326) Cardiovascular Medicine (4769) Dentistry and Oral Medicine (474) Dermatology (407) Emergency Medicine (643) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1614) Epidemiology (15834) Forensic Medicine (32) Gastroenterology (1194) Genetic and Genomic Medicine (6983) Geriatric Medicine (727) Health Economics (1057) Health Informatics (4982) Health Policy (1426) Health Systems and Quality Improvement (1736) Hematology (581) HIV/AIDS (1335) Infectious Diseases (except HIV/AIDS) (16243) Intensive Care and Critical Care Medicine (1161) Medical Education (663) Medical Ethics (151) Nephrology (720) Neurology (7193) Nursing (363) Nutrition (1074) Obstetrics and Gynecology (1231) Occupational and Environmental Health (1001) Oncology (3573) Ophthalmology (1036) Orthopedics (393) Otolaryngology (446) Pain Medicine (466) Palliative Medicine (139) Pathology (704) Pediatrics (1772) Pharmacology and Therapeutics (733) Primary Care Research (759) Psychiatry and Clinical Psychology (5832) Public and Global Health (9690) Radiology and Imaging (2387) Rehabilitation Medicine and Physical Therapy (1432) Respiratory Medicine (1239) Rheumatology (633) Sexual and Reproductive Health (766) Sports Medicine (576) Surgery (766) Toxicology (107) Transplantation (302) Urology (286)
## Related Clinical Research

- [Readers’ reactions: M.D. vs D.O., AI and physician autonomy, surrogacy, postpartum psychiatry, and](https://medichelpline.com/clinical-feed/stat-news-0-opinion-what-stat-readers-think-about-m-d-vs-d-o-ai-in-medicine-surrogacy-and.md)
- [Which interventions affect biological aging? Epigenetic study finds diet, exercise, and some drugs](https://medichelpline.com/clinical-feed/medical-news-today-0-what-can-and-can-t-slow-down-aging-new-study-offers-clues.md)
- [Mass General Brigham drops Dana‑Farber from Medicare Advantage network, affecting cancer patients](https://medichelpline.com/clinical-feed/stat-news-0-stat-top-boston-hospitals-clash-over-medicare-advantage-network-after-split.md)
- [Intensive blood pressure control linked to 15% lower 7-year dementia risk](https://medichelpline.com/clinical-feed/medical-news-today-0-intensive-blood-pressure-control-cuts-7-year-dementia-risk-by-15-study-finds.md)
- [Post-pandemic shifts in respiratory pathogen circulation: Six-year FilmArray® surveillance in Toky](https://medichelpline.com/clinical-feed/medrxiv-18-post-pandemic-ecological-reshaping-of-respiratory-pathogen-circulation-a-six.md)

## Navigation
- [← Back to Gastroenterology Feed](https://medichelpline.com/clinical-feed/gastroenterology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.